Eric Lefkofsky confirms Tempus wins U.S. FDA nod for tumor-only genomic profiling

Eric Lefkofsky confirms Tempus wins U.S. FDA nod for tumor-only genomic profiling
Tempus gains U.S. FDA nod for xT CDx

Tempus achieved a significant development with the U.S. Food and Drug Administration granting approval for a tumor-only indication of xT CDx, according to Eric Lefkofsky.

This regulatory milestone allows use of Tempus’ genomic profiling solution in instances where blood or saliva samples are not feasible. The decision aims to broaden access to advanced genomic profiling, ensuring that more patients can benefit from comprehensive cancer diagnostics, even with limited sample availability.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.